Results 91 to 100 of about 1,266,466 (336)

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Influence of Multiple Traumatic Event Types on Mental Health Outcomes: Does Count Matter? [PDF]

, 2018
The experience of potentially traumatizing events (PTEs) may be associated with conflicting outcomes: individuals may experience greater psychological distress (dose-response theory), or individuals may become more resilient against repeated PTEs (stress-
Brown, Lily A, Contractor, Ateka A, Dranger, Paula, Frankfurt, Sheila B, Gerber, Monica M, Oudshoorn, Kelsey   +5 more
core   +1 more source

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Cancer Medicine, 2018
Radotinib is a second‐generation BCR‐ABL1 tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia in chronic phase (CP‐CML). Here, using the data from a Phase 3 study conducted in patients with newly diagnosed CP‐CML, the dose ...
Hayeon Noh, Su Young Jung, Jae‐Yong Kwak, Sung‐Hyun Kim, Suk Joong Oh, Dae Young Zang, Suhyun Lee, Hye Lin Park, Dae Jin Jo, Jae Soo Shin, Young Rok Do, Dong‐Wook Kim, Jangik I. Lee   +12 more
doaj   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Which is the Right Dose of EU Cohesion Policy for Economic Growth? [PDF]

The current empirical literature on the impact of EU Cohesion Policy on the economic growth rates of the European regions mainly relies on functional form assumptions.
Hagen, Tobias, Mohl, Philipp
core  

Exercise epigenetics and the foetal origins of disease [PDF]

, 2014
Exercise epigenetics is a nascent area of research with vast health implications (e.g., from the treatment of obesity-related diseases to beneficially decoupling epigenetic and chronological age).
Dale E, Thomas EW Chalk, William M Brown
core   +1 more source

The relationship between dietary fiber intake and hypertension: an analysis based on the NHANES data from 2015—2016 in the United States

Zhongguo Linchuang Yixue
ObjectiveTo explore the relationship between dietary fiber intake and hypertension in different populations. MethodsDietary fiber intake was calculated using the data from 2015—2016 National Health and Nutrition Examination Survey (NHANES) database by ...
Linjuan LI, Jiaoyan LI, Xiaoqin LUO
doaj   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Practical considerations for optimal designs in clinical dose finding studies [PDF]

, 2008
Determining an adequate dose level for a drug and, more broadly, characterizing its dose response relationship, are key objectives in the clinical development of any medicinal drug.
Bretz, Frank, Dette, Holger, Pinheiro, Jose   +2 more
core   +1 more source

Confidence bounds for nonlinear dose–response relationships

Statistics in Medicine, 2015
An important aim of drug trials is to characterize the dose–response relationship of a new compound. Such a relationship can often be described by a parametric (nonlinear) function that is monotone in dose. If such a model is fitted, it is useful to know the uncertainty of the fitted curve.
Corine Baayen, Corine Baayen, Philip Hougaard   +2 more
openaire   +4 more sources